KCK MedTech

KCK MedTech

KCK MedTech was established in 2015 by Nael Kassar of the Kassar family. The office maintains headquarters in New York with additional locations in California, London, and Bermuda. Its mandate centers on medical devices and related healthcare technologies. The firm commits across seed, venture, and growth stages through direct co-investments and SPVs. Asset classes include venture capital, private equity, and alternative venture models. Portfolio holdings include NeuroPace, Sight Sciences, Aerin Medical, and Mainstay Medical. Geographic reach covers North America, Europe, and Asia. Co-investment partners include Exor Seeds. All team members previously served in leadership positions at medical technology companies, allowing operational input beyond board participation. No public figure exists for total professionals or aggregate deployment. The office lists seven named investment professionals on its site. Adjacent activity includes sponsorship of the Stanford Biodesign Corporate Program and participation in the Life Science Intelligence Network. No operational events from the past twenty-four months appear in available records. The evergreen structure removes fixed-fund timelines and permits multi-year support for portfolio companies. Team composition supplies functional expertise in regulatory, clinical, and commercial functions that traditional financial investors rarely provide. This operator-led model shapes both sourcing and post-investment engagement.